Aromatase inhibitors and breast cancer

Cancer Treatment Reviews

Volumn 23, Issue 3, 1997, Pages 171-187

  Miller, W R ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; FADROZOLE; FORMESTANE; HYDROCORTISONE; LETROZOLE; VOROZOLE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CHEMICAL STRUCTURE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; SHORT SURVEY;

EID: 0030785796     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(97)90037-2     Document Type: Article

References (112)

1. Miller, W. R. (1996) Aromatase inhibitors End. Related Cancer 3: 65-79.
2. Miller, W. R. (1990) Endocrine treatment for breast cancers: biological rationale and current progress. J. Steroid Biochem. Molec. Biol. 37: 467-480.
3. Miller, W. R. (1989) Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treatment Rev. 16: 83-93.
4. Combs, D. W. (1995) Recent developments in aromatase inhibitors. Expert Opinion on Therapeutic Patents 5: 529-534.
5. Means, G. D., Mahendroo, M., Corbin, C. J. et al. (1989) Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J. Biol. Chem. 264: 19385-19391.
6. Bulun, S. E. & Simpson, E. R. (1994) Regulation of aromatase expression in human tissues. Breast Cancer Res. Treat. 30: 19-29.
7. Johnston, J. O. & Metcalf, B. W. (1984) Aromatase: a target enzyme in breast cancer. In: Novel Approaches to Cancer Chemotherapy, London: Academic Press, pp. 307-328.
8. Santen, R. J. & Misbin, R. I. (1981) Aminoglutethimide: a review of pharmacology and clinical use. Pharmacotherapy 1: 95-120.
9. Vanden Bossche, H., Moereels, H. & Koymans, L. M. H. (1994) Aromatic inhibitors - mechanisms for non-steroidal inhibitors. Breast Cancer Res. Treat. 30: 43-55.
10. 1-testolactone. J. Clin. Endocrinol. Metab. 49: 672-676.
11. 1-Testolactone: clinical trials. Cancer Res. Suppl. 42: 3387-3388.
12. Griffiths, C. T., Hall, T. C., Saba, Z., Barlow, J. J. & Nevinny, H. B. (1973) Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31-37.
13. Lipton, A. & Santen, R. J. (1974) Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer 33: 503-512.
14. Newsome, H. H., Brown, P. N., Terz, J. J. & Lawrence, W. (1977) Medical and surgical adrenalectomy in patients with advanced breast carcinoma. Cancer 39: 542-546.
15. Santen, R. J., Santner, S., Davis, B., Veldhuis, J., Samojlik, E. & Ruby, E. (1978) Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast cancer. J. Clin. Endocrinol. Metab. 47: 1257-1265.
16. Bhatnagar, A. S. & Häusler, A. (1987) Fortschritte in der Entwicklung neuer wirksamer und selektiver Aromatasehemmer. In: Possinger, K. & Miller, W. R., eds, Aromatasehemmer Neuer Perspektiven in der Behandlung des Mammakarzinoms. München: Verlag W. Zuckschwerdt, pp. 23-28.
17. Bhatnagar, A. S., Schieweck, K., Häusler, A., Browne, L. J. & Steele, E. (1989). Inhibitors of oestrogen biosynthesis: preclinical studies with CGS 16949A, a new nonsteroidal aromatase inhibitor. Proc. Roy. Soc. Edin. 95B: 293-303.
18. Santen, R. J., Demers, L. M., Lynch, J. et al. (1991) Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J. Clin. Endocrin. Metab. 73: 99-106.
19. Brodie, A. M. H., Schwarzel, W. C., Sheikh, A. A. & Brodie, H. J. (1977) The effect of an aromatase inhibitor, 4-hydroxyandrostenedione on estrogen-dependent processes in reproduction and breast cancer. Endocrinol. 110: 1684-1695.
20. Brodie, A. M. H., Garnett, W. M., Hendrickson, J. R., Tsai-Morris, C. H., Marcotte, P. A. & Robinson, C. H. (1981) Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids 38: 693-702.
21. Coombes, R. C., Goss, P., Dowsett, M., Gazet, J.-C. & Brodie, A. (1984) 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet ii: 1237-1239.
22. Brodie, A. M. H., Brodie, H. J., Romanoff, L., Williams, J. G., Williams, K. H., & Wu, J. T. (1982) Inhibition of estrogen biosynthesis and regression of mammary tumours by aromatase inhibitors. Hormones Cancer Advanced Exp. Med. Biol. 138: 179-190.
23. Schieweck, K., Bhatnagar, A. S. & Matter A. (1988) CGS16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and independent tumors in vitro. Cancer Res. 48: 834-839.
24. Santen, R. J., Samojlik, E. & Worgul, T. J. (1981) Aminoglutethimide product profile. In: Santen, R. J. & Henderson, I. C. eds. Pharmanual: A Comprehensive Guide to the Therapeutic Use of Aminoglutethimide. Basel: S. Karger, pp. 101-116.
25. Petru, E. & Schmahl D. (1987) On the role of additive monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide on advanced breast cancer. Klinische Wochenschrift 65: 959-966.
26. Cocconi, G. (1994) First generation aromatase inhibitors - aminoglutethimide and testolactone. Breast Cancer Res. Treat 30: 57-80.
27. Lipton, A., Harvey, H. A., Santen, R. J. et al. (1982) A randomised trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 50: 2265-2268.
28. Santen, R. J., Worgul, T. J., Samojlik, E. et al. (1981) A randomised trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. New Eng. J. Med. 305: 545-551.
29. Harris, A. L., Mitchell, M. D., Smith, I. E. & Powles, T. J. (1982) Aminoglutethiomide in the treatment of advanced postmenopausal breast cancer. Cancer Res. Suppl. 42: 3405-3408.
30. 2 by amino-glutethimide in advanced breast cancer. Br. J. Cancer 48: 595-598.
31. Lawrence, D. V., Lipton, A., Harvey, H. A. et al. (1980) Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide. Cancer 45: 786-791.
32. Harris, A. L. (1985) Could aminoglutethimide replace adrenalectomy. Breast Cancer Res. Treat. 6: 201-211.
33. Smith, I. E., Harris, A. L., Morgan, M., Gazet, J-C. & McKenna, J. A. (1982) Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res. 42: 3430-3433.
34. Smith, I. E., Stuart-Harris, R., Harris, A. L. & Dowsett, M. (1984) Aminoglutethimide alone and in combination in the treatment of advanced breast cancer: clinical and endocrine aspects. In: Harvey, H. A., Lipton, A. & Michaels, M. A. eds, Breast Cancer: Therapeutic Modalities, Current and Future. Mississauga, Canada: MES, pp. 145-149.
35. Milsted, R., Habeshaw, T., Kayes, S. et al. (1985) A randomized trial of tamoxifen versus tamoxifen with aminoglutethimide in postmenopausal women with advanced breast cancer. Cancer Chem. & Pharmacol. 14: 272-273.
36. Ingle, J. N., Green, S. J., Ahmann, D. L. et al. (1986) Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J. Clin. Oncol. 4: 958-964.
37. Alonso-Munoz, N. C., Ojeda-Gonzalez, M. B., Beltran-Fabregat, M. et al. (1988) Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncol 45: 350-353.
38. Harris, A. L., Dowsett, M., Cantwell, B. M. J. et al. (1986) Endocrine effects of low dose aminoglutethimide with hydrocortisone - an optimal suppressive regime. Breast Cancer Res. Treat. Suppl. 7: 68-72.
39. Harris, A. L., Dowsett, M., Jeffcoate, S. L., McKenna, J. A., Morgan, M. & Smith, I. E. (1982) Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J. Clin. Endocrinol. Metab. 55: 718-720.
40. Lipton, A., Harvey, H. A., Demers, L. M. et al. (1990) A phase I trial of CGS 16949A. A new aromatase inhibitor. Cancer 65: 1279-1285.
41. Demers, L M., Lipton, A., Harvey, H. A., Hanagen, J., Mulagha, M. & Santen, R. J. (1993) The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. J. Steroid Biochem. Mol. Biol. 44: 683-685.
42. Demers, L. M. (1994) Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res. Treat. 30: 95-102.
43. Falkson, G., Raats, J. I. & Falkson, H. C. (1992) Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer. J. Steroid Biochem. Mol. Biol. 43: 161-165.
44. Höfken, K. (1993). Experience with aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat. Rev. 19 (Suppl. B): 37-44.
45. Bonnefoi, H. R., Smith, I. E., Dowsett, M. et al. (1996) Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. Br. J. Cancer 173: 539-542.
46. Buzdar, A. U., Jonat, W., Howell, A. et al. (1996) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J. Clin. Oncol. 14: 2000-2011.
47. Thurlimann, B., Beretta, M., Bacchi, M. et al. (1996) First-line fadrozole hci (cgs-16949a) versus tamoxifen in postmenopausal women with advanced breast cancer - prospective randomised trial of the Swiss Group for Clinical Cancer Research saKK-20/88. Ann. Oncol. 7: 471-497.
48. Demers, L M., Melby, J. C., Wilson, T. E., Lipton, A., Harvey, G. A. & Santen, R. J. (1990) The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. J. Clin. Endocrinol. Metab. 70: 1162-1166.
49. Stein, R. C., Dowsett, M., Hedley, A., Ford, H. T., Gazet, J. C. & Coombes, R. C. (1990) Preliminary study of the treatment of advanced breast cancer in postmenopausal women with aromatase inhibitor CGS 16949A. Cancer Res. 50: 1381-1384.
50. Dowsett, M., Smithers, D., Moore, J. et al. (1994) Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur. J. Cancer 30A: 1453-1458.
51. Coombes, R. C., Goss, P. E. & Dowsett, M. et al. (1987) 4-hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids 50: 245-252.
52. Stein, R. C., Dowsett, M. & Coombes, R. C. (1994) Studies of formestane alone and in combination with goserelin in premenopausal breast cancer. Advances Clin. Oncol. 2: 149-154.
53. Cunningham, D., Powles, T. J., Dowsett, M. et al. (1987) Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemo. Pharmacol. 20: 253-255.
54. Dowsett, M., & Coombes, R. C. (1994) Second generation aromatase inhibitor - 4-hydroxyandrostenedione. Breast Cancer Res. Trest. 30: 81-87.
55. Dowsett, M., Goss, P. E., Powles, T. J. et al. (1987) Use of aromatase 4-hydroxy-androstenedione in postmenopausal breast cancer. Optimization of therapeutic dose and route. Cancer Res. 47: 1957-1961.
56. Dowsett, M., Cunningham, D. C., Stein, R. C. et al. (1989) Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 49: 1306-1312.
57. Coombes, R. C., Stein, R. C. & Dowsett, M. (1989) Aromatase inhibitors in human breast cancer. Proc. Roy. Soc. Edin. 95B: 283-291.
58. Hoffken, K., Jonat, W., Possinger, K. et al. (1990) Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. J. Clin. Oncol. 8: 875-880.
59. Pickles, T., Perry, L., Murray, P. & Plowman, P. (1990) 4-hydroxyandrostenedione - Further clinical and extended endocrine observations. Br. J. Cancer 62: 309-313.
60. Santen, R. J., Manni, A., Harvey, H. & Redmond, C. (1990) Endocrine treatment of breast cancer in women. End. Rev. 11: 1-45.
61. Stein, R. C., Dowsett, M., Medley, A., Gazet, J. C., Ford, H. T. & Coombes, R. C. (1990) The clinical end endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Brit. J. Cancer 52: 679-683.
62. Goss, P. E. & Gwyn, K. M. E. H. (1994) Current perspectives on aromatase inhibitors in breast cancer. J. Clin. Oncol. 12: 2460-2470.
63. Murray, R., & Pitt, P. (1985) Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. Eur. J. Cancer Clin. Oncol. 21: 19-22.
64. Lonning, P. E., Dowsett, M., Jones, A. et al. (1992) Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxy-androstenedione treatment. Breast Cancer Res. Treat 23: 57-62.
65. Bajetta, E., Zilembo, N., Buzzoni, R., Noberasco, C., Celio, L. & Bichisao, E. (1993) Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy. Cancer Treat. Rev. 19 (Suppl. B): 31-36.
66. Perez-Carrion, R., Alberola, C. V., Calabresi, F. et al. (1994) Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann. Oncol. 5: S19-S24.
67. Plourde, P. V., Dryoff, M. & Dukes, M. (1994) Arimidex (TM): A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat. 30: 103-111.
68. Demers, L. M., Lipton, A., Harvey, H. A. et al. (1993) The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J. Steroid Biochem. 44: 687-691.
69. Iveson, T. J., Smith, I. E., Ahern, J., Smithers, D. A., Trunet, P. F. & Dowsett, M. (1993) Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 53: 266-270.
70. Johnston, S. R. D., Smith, I. E., Doody, D., Jacobs, S., Robertshaw, H. & Dowsett, M. (1994) Clinical and endocrine effects of the oral aromatase inhibitor Vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 54: 5875-5881.
71. Lonning, P. E. (1996) Pharmacology of new aromatase inhibitors. The Breast 5: 202-208.
72. Geisler, J., King, N., Dowsett, M. et al. (1996) Influence of anastrozole (arimidex), a selective, nonsteroidal aromatase inhibitor, on in vivo aromatization and plasma estrogen levels in postmenopausal women with breast cancer. Br. J. Cancer 74: 1286-1291.
73. Jonat, W., Howell, A., Blomqvist, C. et al. (1996) A randomized trial comparing 2 doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol-acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 32A: 404-412.
74. Buzdar, A. U., Jonat, W., Howell, A. et al. (1996) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J. Clin. Oncol. 14: 2000-2011.
75. Bhatnagar, A. S., Hausler, A., Schieweck K., Lang, M. & Bowman, R. (1995) Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 37: 1021-1027.
76. Dowsett, M. (1996) Biological background to aromatase inhibition. The Breast 5: 196-201.
77. Smith, I. E., Iveson, T. J., Trunet, P. & Dowsett, M. (1994) CGS20267, a new oral non-steroidal aromatase inhibitor in the treatment of postmenopausal patients with advanced breast cancer: a phase I clinical study. Adv. Clin. Oncol. 2: 179-185.
78. Lipton, A., Demers, L M., Harvey, H. A. et al. (1995) Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 75: 2132-2138.
79. van der Wall, E., Donker, T. H., de Frankrijker, E., Nortier, H. W. R., Thijssen, J. H. H. & Blankenstein, R. A. (1993) Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res. 53: 4563-4566.
80. Wouters, W., Snoeck, E. & De Coster, R. (1994) Vorozole, a specific non-steroidal aromatase inhibitor. Breast Cancer Res. Treat. 53: 4563-4566.
81. Goss, P. E., Clark, R. M., Ambus, U. et al. (1995) Phase II study of Vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamofixen. Clin. Cancer Res. 1: 287-294.
82. Howell, A. (1996) New endocrine treatments for breast cancer: biological and clinical aspects. The Breast 5: 170-174.
83. Santen, R. J., Samojlik, E. & Wells, S. A. (1980) Resistance of the ovary to blockade of aromatization with aminoglutethimide. J. Clin. Endocrinol. Metab. 51: 473-477.
84. Harris, A. L., Dowsett, M., Jeffcoate, S. L., McKenna, J. A., Morgan, M. & Smith, I. E.. (1982) Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J. Clin. Endocrinol. Metab. 55: 718-720.
85. Wander, H. E., Blossey, H. Ch., & Nagel, G. A. (1986) Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur. J. Cancer Clin. Oncol. 22: 1371-1374.
86. Wouters, W., De Coster, R., Tuman, R. W. et al. (1989) Aromatase inhibition by R76713: experimental and clinical pharmacology. J. Steroid Biochem. 34: 427-430.
87. Blarney, R. W. & Dixon, A. R. (1991) LHRH analogues. In: Powles, T. J. & Smith, I. E., eds, Medical Management of Breast Cancer. London: Dunitz, pp. 109-114.
88. Love, R. R., Mazess, R. B., Barden, H. S. et al. (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New Engl. J. Med. 326: 852-856.
89. Miller, W. R. (1996) Aromatase inhibitors. End. Related Cancer 3: 65-79.
90. Miller, W. R. & O'Neill, J. S. (1989) The relevance of local estrogen metabolism within the breast. Proc. Roy. Soc. (Edin.) 95B: 203-217.
91. Bezwoda, W. R., Mansoor, N. & Dansey, R. (1987) Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. Oncol. 44: 345-349.
92. Miller, W. R. & O'Neill, J. S. (1988) The importance of local synthesis of estrogen within the breast. Steroids 50: 537-548.
93. Allegra, J. C., Barlock, A., Huff, K. K. et al. (1980) Changes in multiple or sequential estrogen receptors in breast cancer. Cancer 45: 792-794.
94. Hawkins, R. A., Tesdale, A. L., Anderson, E. D. C. et al. (1990) Does the oestrogen receptor concentration of a breast cancer change during systemic therapy? Br. J. Cancer 6: 877-880.
95. Miller, W. R., Hawkins, R. A., Mullen, P., Sourdaine, P. & Telford, J. (1995) Aromatase inhibition: determinants of response and resistance. End. Related Cancer 2: 73-85.
96. Fuqua, S. A. W., Wiltschke, C, Castles, C., Wolf, D. & Allred, D. C. (1995) A role for estrogen-receptor variants in endocrine resistance. End. Related Cancer 2: 19-25.
97. Fujimoto, N. & Katzenellenbogen, B. S. (1994) Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signalling pathways in breast cancer cells: antiestrogen-selectivity and promoter-dependence. Mol. Endocrinol. 8: 296-304.
98. Isaacs, J. T. (1988) Clonal heterogeneity in relation to response. In: Stoll, B. A. ed. Endocrine management of cancer: biological bases. Basel: Karger: 125-140.
99. Howell, A., Defriend, D. & Anderson, E. (1995) Clues to the mechanism of endocrine resistance from clinical studies in advanced breast cancer. End. Related Cancer 2: 131-139.
100. Santen, R. J. (1982) Overall experience with aminoglutethimide in the management of advanced breast cancer. In: Elsdon-Dew, R. W., Jackson, I. M., Birdwood, G. F. B. eds. Aminoglutethimide: an Alternative Endocrine Therapy for Breast Carcinoma. London: Academic Press: 3.
101. Herman, M. E. & Katzenellenbogen, B. (1994) Alterations in transforming growth factor-α and -β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54: 5867-5874.
102. King, R. J. B., Wang, D. Y., Daly, R. J. & Darbre, P. D. (1989) Approaches to studying the role of growth factors in the progression of breast tumours from the steroid sensitive to insensitive state. J. Steroid Biochem. 34: 133-138.
103. Kadohama, N., Yarborough, C., Zhou, D., Chen, S. & Osawa, Y. (1992) Kinetic properties of aromatase mutants Pro308Phe, Asp309Asn and Asp309Ala and their interactions with aromatase inhibitors. J. Steroid Biochem Mol. Biol. 43: 693-701.
104. James, V. H. T., Reed, M. J., Adams, E. F. et al. (1989) Oestrogen uptake and metabolism in vivo. Proc. Roy. Soc. Edin. 95B: 185-193.
105. Miller, W. R. (1992) In vitro and in vivo effects of 4-hydroxyandrostenedione on steroid and tumour metabolism. In: Coombes, R. C. & Dowsett, M. eds, 4-Hydroxy-androstenedione - A New Approach to Hormone-dependent Cancer. London: Royal Society of Medicine Services Ltd. International Congress and Symposium Series, pp. 45-50.
106. Sourdaine, P., Parker, M. G., Telford, J. & Miller, W. R. (1994) Analysis of the aromatase cytochrome P450 gene in human breast cancer. J. Mol. Endocrinol. 13: 331-337.
107. Bocuzzi, G., Brignardello, E., Dimonaco, D., Forte, C., Leonardi, L. & Piizzini, A. (1992) Influence of dehydroepiandrosterone and 5-en-androstene-3-beta, 17-beta-diol on the growth of MC-7 human breast cancer cells induced by 17-beta estradiol. Anticancer Res. 12: 799-803.
108. Ginsburg, E. (1994) Environmental oestrogens. Lancet 343: 284-285.
109. Sharpe, R. (1994) Could environmental oestrogenic chemicals be responsible for some disorders of human male reproductive development? Current Opinion Urol. 4: 295-301.
110. Setchell, K. D. P., Borriello, S. P., Hulme, P., Kirk, D. N. & Axelson, M. (1984) Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am. J. Clin. Nutr. 40: 569-578.
111. Yue-W., Wang, J. P., Savinov, A. & Brodie, A. (1995) Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res. 55: 3073-3077.
112. van Ginckel, R., Janssens, B., Callens, M, Goeminne, N., Wouters, L. & de Coster, R. (1996) Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene induced mammary-carcinoma in the rat. Cancer Chemo. Pharmacol. 38: 21-28.